Mrs Allison Conrad Matunas, PT in Arlington, VT - Physical Therapist

Mrs Allison Conrad Matunas, PT is a Physical Therapist based in Arlington, Vermont. Mrs Allison Conrad Matunas is licensed to practice in Vermont (license number 0400003556) and her current practice location is 2802 Route 7a, Arlington, Vermont. She can be reached at her office (for appointments etc.) via phone at (802) 375-9200.

NPI number for Mrs Allison Conrad Matunas is 1073551792 and her current mailing address is Po Box 892, Arlington, Vermont. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1073551792.

Contact Information

	Mrs Allison Conrad Matunas, PT
	2802 Route 7a, Arlington, VT 05250
	(802) 375-9200
	(802) 375-9288

Healthcare Provider's Profile

Full Name	Mrs Allison Conrad Matunas
Gender	Female
Speciality	Physical Therapist
Location	2802 Route 7a, Arlington, Vermont
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1073551792
Provider Enumeration Date: 06/03/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Mrs Allison Conrad Matunas such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1073551792	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225100000X	Physical Therapist	0400003556 (Vermont)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mrs Allison Conrad Matunas is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mrs Allison Conrad Matunas, PT Po Box 892, Arlington, VT 05250-0892 Ph: (802) 375-9200	Mrs Allison Conrad Matunas, PT 2802 Route 7a, Arlington, VT 05250 Ph: (802) 375-9200

News Archive

Two-hormone combo test predicts prostate cancer risk

New research presented at the NCRI Cancer Conference, 2019, shows that free testosterone and insulin-like growth factor-1 (IGF-I), when present at high levels in combination, show a higher risk of prostate cancer in men. This finding is important since both these factors can be counteracted, to possibly reduce the risk.

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma's formulation of MoxDuo IV resulted in fewer side effects and offered better pain relief than morphine alone.

OncoSec to purchase $7.75M of securities in registered public offering

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase $7.75 million of securities in a registered public offering.

Low-Income Subsidies for the Medicare Prescription Drug Benefit: The Impact of the Asset Test

An estimated 2.4 million Medicare beneficiaries with incomes low enough to qualify for additional subsidies under the new Medicare drug benefit are expected to be ineligible for these subsidies because they do not meet the asset test required by law, according to a new study from the Kaiser Family Foundation.

Sulindac shuts down cancer cell growth, initiates cell death: Study

Without knowing exactly why, scientists have long observed that people who regularly take non-steroidal anti-inflammatory drugs like aspirin have lower incidences of certain types of cancer. Now, in a study appearing in Cancer Cell on June 15, investigators at Sanford-Burnham Medical Research Institute and their colleagues have figured out how one NSAID, called Sulindac, inhibits tumor growth.

Mrs Allison Conrad Matunas, PT - Physical Therapist in Arlington, VT